A dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and obesity.
BACKGROUND: Heart failure with preserved ejection fraction is common, obesity-related, and associated with high symptom burden and healthcare use. Tirzepatide, a dual GIP/GLP-1 receptor agonist, improved symptoms and outcomes in SUMMIT, but its acqui…
BACKGROUND: Nutritional deficiencies are common among people with obesity, before and during treatment, such as with very-low-calorie diets and metabolic/bariatric surgery. Obesity management medications (OMMs) can reduce appetite and dietary intake,…
BACKGROUND: Peptide therapeutics represent an emerging frontier in gerontological medicine, targeting fundamental hallmarks of aging including metabolic dysfunction, telomere attrition, tissue repair impairment, and hormonal decline. OBJECTIVE: To co…
BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) has emerged as the predominant of heart failure (HF), particularly among aging populations and individuals with a high burden of comorbidities. Its underlying pathophysiological mecha…
Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease now targeted by new pharmacotherapies, including the thyroid hormone receptor beta (THR-β) agonist resmetirom, glucagon-like peptide-1 (GLP-1) receptor agonists (s…
Glucagon-like peptide-1 (GLP-1) therapies are under investigation for a growing number of neuropsychiatric conditions, including substance use disorders. Cigarette smoking accounts for the largest proportion of substance use-related morbidity and mor…
OBJECTIVES: Depression, diabetes, and obesity often coexist, forming a complex "metabolic-mood syndrome" characterized by inflammation, impaired neuroplasticity, and neuroendocrine dysregulation. Conventional antidepressants show limited efficacy in…
BACKGROUND: Sepsis-associated acute lung injury (ALI) is characterized by unregulated systemic inflammation, disruption of the redox balance, and impaired pulmonary function. Tirzepatide, a synthetic dual GLP-1 and GIP receptor agonist possessing ant…
AIMS: Tirzepatide, an injectable glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist (RA), is approved for weight management in several regions. Oral GLP-1 RAs, such as semaglutide, are under invest…
BACKGROUND: Real-world data directly comparing the safety, tolerability, and effectiveness of semaglutide and tirzepatide in patients with obesity remain limited. This nationwide multicenter observational study compared short-term adverse events, tre…
BACKGROUND: Obesity is characterized by chronic inflammation and fibrosis of adipose tissue; however, the extent to which these pathological features persist during pharmacologically induced weight loss remains poorly understood. This study investiga…
OBJECTIVE: To evaluate shifts in waist-to-height ratio (WHtR) categories among adults with obesity or overweight, with or without prediabetes, treated with tirzepatide in the SURMOUNT-1 study. METHODS: This post hoc analysis included 2,538 participan…
Glucagon-like peptide-1 (GLP-1)-based obesity pharmacotherapies have revolutionized obesity treatment. In this review, we discuss the discovery of GLP-1 and evaluate the efficacy of marketed and investigational GLP-1 receptor (GLP-1R) agonists (GLP-1…
Two out of 5 US adults live with obesity, generating substantial clinical and economic burden. Recent glucagon-like peptide-1 receptor agonists (GLP-1 RAs), including semaglutide and tirzepatide, demonstrate significant weight loss and cardiometaboli…
OBJECTIVES: Obesity management has limited oral pharmacotherapies. Bitter taste receptor (TAS2R) agonists may modulate hunger, satiety, and metabolism via gut-brain signaling. We evaluated denatonium acetate (DA), a gut-restricted TAS2R agonist, acro…
BACKGROUND: This study evaluated the safety of compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) compared to non-compounded formulations using the U.S. FDA Adverse Event Reporting System (FAERS). RESEARCH DESIGN AND METHODS: A retrospe…